---
title: "This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300792961.md"
description: "Wall Street analysts initiated coverage on five stocks with bullish outlooks. BMO Capital rated VYLR Outperform ($85), Needham rated LBRX Buy ($68), Morgan Stanley rated ELVN Overweight ($70), Keybanc rated SAIL Sector Weight, and Raymond James rated AVLN Outperform ($60). These initiations reflect positive analyst sentiment for the listed companies."
datetime: "2026-10-02T12:24:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300792961.md)
  - [en](https://longbridge.com/en/news/300792961.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300792961.md)
generator: "portal-rs"
---

# This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   BMO Capital analyst Joel Jackson initiated coverage on **Vylor, Inc.** (NYSE:VYLR) with an Outperform rating and announced a price target of $85. Vylor closed at $68.26 on Thursday. See how other analysts view this stock.
-   Needham analyst Ami Fadia initiated coverage on **LB Pharmaceuticals Inc** (NASDAQ:LBRX) with a Buy rating and announced a price target of $68. LB Pharmaceuticals shares closed at $37.28 on Thursday. See how other analysts view this stock.
-   Morgan Stanley analyst Sean Laaman initiated coverage on **Enliven Therapeutics In**c (NASDAQ:ELVN) with an Overweight rating and announced a price target of $70. Enliven Therapeutics closed at $46.21 on Thursday. See how other analysts view this stock.
-   Keybanc analyst Eric Heath initiated coverage on **Sailpoint Inc** (NASDAQ:SAIL) with a Sector Weight rating. SailPoint shares closed at $20.58 on Thursday. See how other analysts view this stock.
-   Raymond James analyst Tiago Fauth initiated coverage on **Avalyn Pharma Inc** (NASDAQ:AVLN) with an Outperform rating and announced a price target of $60. Avalyn Pharma closed at $27.42 on Thursday. See how other analysts view this stock.

Considering buying ELVN stock? Here’s what analysts think:

*Photo via Shutterstock*

### Related Stocks

- [AVLN.US](https://longbridge.com/en/quote/AVLN.US.md)
- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)
- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)
- [SAIL.US](https://longbridge.com/en/quote/SAIL.US.md)
- [VYLR.US](https://longbridge.com/en/quote/VYLR.US.md)

## Related News & Research

- [Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/300873957.md)
- [Vylor has scarcity value, says Jim Cramer](https://longbridge.com/en/news/300833366.md)
- [Kuehn Law Encourages Investors of SailPoint, Inc. to Contact Law Firm](https://longbridge.com/en/news/300586083.md)
- [Corteva split into 2 companies and Wall Street sees big upside in both stocks](https://longbridge.com/en/news/300805575.md)
- [Corteva spinoff of Vylor clears after California bid to block separation fails](https://longbridge.com/en/news/300668361.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**